1. Fisher RI, Miller TP, Grogan TM. New REAL clinical entities. Cancer J Sci Am. 1998;4:S5–S12.
2. NCCN clinical practice guidelines in oncology: non-Hodgkin lymphoma Version 4.2014.
3. 2014-yılı-türkiye-kanser-istatistikleri. https://hsgm.saglik.gov.tr/tr/kansistatistikleri/yillar/495-2014-yili-türkiye-kanser-istatistikleri.html.
4. Rizzieri D. Zevalin((R)) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol. 2016;105:5–17.
5. EANM procedure guideline of radio-immunotherapy for B-cell lymphoma with 90Y- radiolabeled ibritumomab tiuxetan (Zevalin®).